Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.60 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329691 | 0.86 | GBA1 (0.64) | GBA1FUCA1PYGLGRIN2BRORC | |
| SCHEMBL6953561 | 0.86 | GBA1 (0.64) | GBA1FUCA1PYGLGRIN2BRORC | |
| Bromide SCHEMBL1943491 | 0.85 | GBA1 (0.63) | GBA1FUCA1PYGLGRIN2BRORC | |
| Bromide SCHEMBL4532368 | 0.85 | GBA1 (0.63) | GBA1FUCA1PYGLGRIN2BRORC | |
| Bromide SCHEMBL2683848 | 0.85 | GBA1 (0.63) | GBA1FUCA1PYGLGRIN2BRORC | |
| SCHEMBL6042917 | 0.85 | GBA1 (0.63) | GBA1FUCA1PYGLRORC | |
| SCHEMBL4528469 | 0.78 | GBA1 (0.82) | GBA1FUCA1PYGL | |
| SCHEMBL500739 | 0.78 | GBA1 (0.82) | GBA1FUCA1PYGL | |
| SCHEMBL500738 | 0.78 | GBA1 (0.82) | GBA1FUCA1PYGL | |
| SCHEMBL6042716 | 0.76 | KDM1A (0.56) | FUCA1LTA4HKDM1AS1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | GBA1 158/4885FUCA1 605/4885LTA4H 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.